Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose-finding based on efficacy-toxicity trade-offs.

Peter F Thall1, John D Cook

  • 1Department of Biostatistics and Applied Mathematics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. rex@mdanderson.org

Biometrics
|September 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes.

Statistics in medicine·2026
Same author

High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Precision generalized phase I-II designs.

Biometrics·2025
Same author

Practical Bayesian Guidelines for Small Randomized Oncology Trials.

Cancers·2025
Same author

Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility-Based Rule.

Statistics in medicine·2024
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

This adaptive Bayesian method optimizes clinical trial dose selection by balancing treatment efficacy and toxicity. It ensures most patients receive effective doses with minimal side effects, improving trial outcomes.

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Traditional dose-finding methods often struggle with complex outcome probabilities.
  • Balancing treatment efficacy and toxicity is crucial in early-phase clinical trials.

Purpose of the Study:

  • To introduce a novel adaptive Bayesian approach for dose-finding in Phase I/II clinical trials.
  • To accommodate complex outcomes, including non-monotone dose-efficacy relationships.
  • To optimize patient treatment by considering efficacy-toxicity trade-offs.

Main Methods:

  • Developed an adaptive Bayesian framework utilizing efficacy-toxicity trade-off contours.
  • Incorporated methods for trinary and bivariate binary outcomes.
  • Established priors by optimizing model fit to elicited probabilities.

Related Experiment Videos

Main Results:

  • Simulations demonstrate high accuracy in decision-making across various dose-outcome scenarios.
  • The method effectively identifies doses with favorable efficacy-toxicity profiles.
  • Applied to real-world examples in ischemic stroke and bone marrow transplantation.

Conclusions:

  • The proposed Bayesian method offers a robust and adaptive solution for dose-finding.
  • It enhances clinical trial efficiency by maximizing desirable efficacy-toxicity balances.
  • Applicable to diverse clinical settings requiring nuanced dose optimization.